hotspot -WSS

hotspot

author：explore 2025-10-03 00:37:49 - browse：266

Dr. Peter Bach — Peter Bach, shown at the 2019 STAT summit, is now chief medical officer of Delfi. Emilie Pickering for STAT

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening.

The approach represents a new one in the field of liquid biopsy, in which DNA fragments in blood are used to detect or learn about tumors. Grail, another company developing a blood test for cancer screening, has insisted that its product would be best used to detect multiple cancers at once. Other companies, including Exact Sciences and Freenome, are developing tests that would focus on detecting colorectal cancer. But Delfi appears to be the first to focus first on lung cancer, the leading cause of cancer death.

Delfi’s executives, in an interview with STAT, were clear that they view the initial launch as an opportunity to gather information, and not a real commercial coming out. The test will likely become available in limited ways with specific partners and will not initially be covered by insurance. Delfi declined to reveal a specific price, but said that its early access customers, which it is not yet disclosing, will be able to use FirstLook Lung for several hundred dollars. Such a rollout does not require approval from the Food and Drug Administration, which Delfi does not have.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Dario to buy mental health app maker Twill in cash and stock deal

leisure time

WSS

PBM reform efforts get punted in Congress

He's a Nobel laureate. Critics say he was misleading on Covid

PBM reform efforts get punted in Congress

Baltimore teen accused of firing into crowd during block party mass shooting

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

ProMED sees offers of support, but its future remains unclear

hotspot

hotspot

hotspot

Supreme Court strikes down use of affirmative action

Alabama frozen embryo ruling has major implications for IVF clinics

Malaria cases in Florida and Texas: Here’s what you need to know

Majority of Americans think Trump's Ga. election interference case is serious: POLL

As demand for Covid shots wanes, Moderna seeks its next success

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Hepatitis C has a cure — but many Americans still lack access to it

Alabama hospital puts IVF treatments on hold

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Wikipedia

Community Health Systems hospitals under DOJ investigation

Hilary expected to bring catastrophic, life

FDA approves first treatment for ultra

Patient advocates sound warning on FDA proposal on salt intake

Evacuations in place as 3 wildfires burn in eastern Washington state

ActiGraph execs on goal of drug approvals with digital endpoints

explore

leisure time

explore

focus